百济神州公告，第三季度总收入14.12亿美元，同比增长41%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 本公司欣然公佈本公司及其附屬公司截至2025年9月30日止三個月及九個月未經 審核簡要合併財務業績（「第三季度業績」）以及2025年第三季度關鍵業務亮點和更 新2025年年度財務指引（「業務進展」）。第三季度業績乃根據美國證券交易委員會 的適用規則刊發。 第三季度業績乃根據美國公認會計準則編製，而美國公認會計準則有別於國際財 務報告準則。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 內幕消息 百濟神州有限公司 截至2025年9月30日止三個月及九個月未經審核業績以及 業務進展最新情況 本公告乃根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及 根據證券及期貨條例（香港法例第571章）第XIVA部而刊發。 百濟神州有限公司（「本公司」或「百濟神州」）欣然公佈其截至2025年9月30日止 三個月及九個月的未經審核簡要 ...

Exhibit 99.1 BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates • Third quarter total revenues increased 41% to $1.4 billion versus third quarter 2024 • Global BRUKINSA (zanubrutinib) revenues increased 51% to $1.0 billion versus third quarter 2024 ® • Diluted GAAP Earnings per American Depository Share (ADS) of $1.09, non-GAAP diluted Earnings per ADS of $2.65 • 47 abstracts accepted at American Society of Hematology (ASH) Annual Meeting Exhibit 99.1 Third Quarter 2025 Fina ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百濟神州有限公司 (根據瑞士法律註冊成立的公司) 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06160 | 說明 | 請見備注 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,311,463,847 | USD | | 0.0001 USD | | 231,146.38 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,311,463,847 | USD | | 0.0001 USD | | 231,14 ...

Group 1 - The article provides a list of companies scheduled for various corporate events on November 6, 2025, including shareholder meetings and earnings announcements [1][4]. - Companies mentioned include major players such as Jiesheng Electronics, Xiaoma Zhixing-W, and Wenyuan Zhixing-W, indicating a busy day for the Hong Kong stock market [5]. - The article highlights the significance of these events for investors, as they may impact stock performance and market sentiment [5]. Group 2 - Specific events listed include earnings announcements, dividend distributions, and stock rights issues for companies like Meilan Airport and Huasheng Holdings [5]. - The presence of multiple companies from various sectors suggests a diverse range of investment opportunities on that date [5]. - The article emphasizes the importance of monitoring these events for potential investment strategies and market movements [5].

Core Insights - In October, the net value return of the GF CSI Hong Kong Innovative Drug ETF (QDII) decreased by 11.61% due to fluctuations in the Hong Kong stock market [1] - The fund's scale reached 24.889 billion yuan, with the top ten holdings including companies like Innovent Biologics, BeiGene, WuXi Biologics, and others [1] - The fund manager, Liu Jie, has over 10 years of experience in managing public funds since 2014 [1] Fund Performance - The GF CSI Hong Kong Innovative Drug ETF (QDII) reported a net value growth rate of -11.61% with a net value of 1.3337 yuan and a total scale of 24.889 billion yuan [2] - The GF CSI Hong Kong Innovative Drug ETF Initiated Link (QDII) C and A also experienced declines of over 11% in October, with net values of 1.3853 yuan and 1.3937 yuan respectively [2] - The largest holding, Innovent Biologics, saw a decline of 9.75% in October, while another major holding, CanSino Biologics, dropped over 19% [1]

Core Insights - The pharmaceutical industry is experiencing a structural change driven by the growth cycles of major products, with significant opportunities emerging in innovative drugs, medical devices, and consumer healthcare [3][6][31] - The demand for pharmaceuticals is expected to improve in 2026, supported by policies encouraging innovation and a recovery in domestic consumption [3][7] - The supply side of the pharmaceutical industry is characterized by high entry barriers due to patent protections and government regulations, which helps maintain a stable competitive environment [4][5] Group 1: Industry Trends - The aging population, urbanization, and changing disease patterns are making the pharmaceutical industry a perpetual growth sector [3] - The global pharmaceutical market has seen rapid expansion from 2009 to 2019, followed by a surge in demand due to COVID-19, and is now entering a phase of recovery and growth [3][6] - The Chinese pharmaceutical industry is expected to gradually produce world-class companies, with increasing recognition of Chinese innovative drug assets by multinational corporations (MNCs) [4][5] Group 2: Investment Opportunities - Opportunities in innovative drugs are highlighted, particularly in oncology, metabolic diseases, and autoimmune diseases, with a focus on next-generation therapies and precision medicine [6][31] - The demand for innovative drugs is expected to remain strong, with policies improving medical insurance payments and the upcoming launch of commercial insurance drug catalogs [7][31] - The medical device sector is anticipated to recover, with a focus on domestic demand and international expansion, particularly in areas with low domestic production rates [7][8] Group 3: Company Performance - Major pharmaceutical companies like Eli Lilly, AbbVie, and AstraZeneca are experiencing significant growth driven by key products, with Eli Lilly's Tirzepatide generating $24.8 billion in sales [12][15] - The report identifies specific companies such as Hengrui Medicine, Hansoh Pharmaceutical, and BeiGene as outperformers in the market, with strong pipelines and global competitiveness [7][8] - The report emphasizes the importance of mergers and acquisitions (M&A) and business development (BD) strategies for MNCs, with China becoming a significant source of projects for top global pharmaceutical companies [22][24]

Core Insights - The pharmaceutical industry is positioned as a perennial growth sector due to aging populations, urbanization, and changing disease profiles, with a strong recovery expected in 2025 after a downturn from 2022 to 2024, driven by both innovative drugs and medical devices [2][3] - Demand and supply dynamics will remain central to the pharmaceutical industry's research, with innovation cycles and policy adjustments influencing demand growth [2][3] - The supply side is characterized by limited supply and high entry barriers, with increasing participation of Chinese companies in international competition, leading to the emergence of world-class enterprises in the pharmaceutical sector [3][4] Industry Overview - The pharmaceutical industry is expected to see significant growth in 2025, driven by a resurgence in demand for innovative drugs and a recovery in domestic medical device needs, alongside strong external demand [2] - The demand for pharmaceuticals typically fluctuates with innovation and policy cycles, with a notable increase in overseas business development (BD) opportunities anticipated in 2025 [2][5] - The Chinese pharmaceutical sector is increasingly recognized globally, with local companies making strides in various niche markets [3][4] Investment Opportunities - Opportunities in innovative drugs are highlighted, particularly in oncology, metabolic diseases, and autoimmune diseases, with a focus on next-generation therapies and precision medicine [5][29] - The report emphasizes the importance of understanding the supply-demand structure and industry upgrades when conducting detailed research on specific segments within the pharmaceutical industry [4][5] - The report identifies key players and segments for investment, including CXO services, medical devices, and consumer healthcare, with specific companies recommended for increased holdings [6][5] Market Dynamics - The report outlines the competitive landscape among top global pharmaceutical companies, noting significant changes in rankings due to the performance of key products [11][19] - Chinese companies are becoming a major source of projects for multinational corporations (MNCs), with increasing transaction volumes and values in recent years [19][21] - The report discusses the strategic focus of MNCs on acquiring innovative assets and technologies to strengthen their market positions, particularly in oncology and metabolic disease sectors [12][18] Future Trends - The report anticipates breakthroughs in various therapeutic areas, including oncology, metabolic diseases, and autoimmune diseases, with a focus on innovative treatment modalities such as TCE and in vivo CAR-T [29][30] - The small nucleic acid field is expected to accelerate, with significant advancements anticipated in 2026 across multiple indications [29][30] - The report highlights the importance of collaboration and co-development models as a means for Chinese companies to enhance their global competitiveness [25][28]

Core Insights - The establishment of the Overseas Returnee Town in Guangzhou's Huangpu District has attracted around 30 well-known innovative enterprises and projects, creating a vibrant entrepreneurial ecosystem for returnees [3][5][11] - The region has developed a complete biopharmaceutical industry chain, facilitating research, transformation, and production, which supports companies at various stages of development [3][5][11] - The "1+N" multi-core model of the town promotes regional collaboration and has become a hub for returnee talent to start their businesses [4][5] Industry Development - The core area of the Overseas Returnee Town spans 3.8 square kilometers, with an additional 4.2 square kilometers for future expansion, forming a comprehensive biopharmaceutical innovation ecosystem [5] - Leading companies such as BeiGene, CanSino Biologics, and Innovent Biologics have established a presence in the town, contributing cutting-edge ideas and technologies while attracting more overseas talent [5][6] - The dual-center support system, including the Phoenix Valley Returnee Center and the International Biopharmaceutical Innovation Center, provides comprehensive services for the ecosystem [5][6] Talent and Investment - The returnee town is strategically aligned with the industrial upgrade of Guangzhou, which has recognized the potential of the biopharmaceutical sector since the late 1990s [7][8] - The government has implemented innovative models combining physical space provision, talent attraction, and market-oriented management, with a guiding fund of 2 billion yuan aimed at attracting social capital [8] - Approximately 76.11 billion yuan has been invested in 274 enterprises, with 18.54 billion yuan specifically directed towards returnee startups [11] Innovation and Collaboration - The Guangzhou National Laboratory on the Biopharmaceutical Island has successfully attracted high-level researchers from abroad, facilitating the transformation of research outcomes into industry applications [9] - The region is focusing on international collaborations, leveraging its advantages in scientific research to establish a leading position in biopharmaceutical innovation [8][9] - The integration of various resources has created a robust innovation network, with around 4,800 biopharmaceutical companies thriving in the area [11]

Core Insights - The establishment of the Overseas Returnee Town (Guangzhou Biomedicine) in the Guangzhou Development Zone and Huangpu District has become a hub for returning talents and innovative enterprises in the biomedicine sector, showcasing a successful model for attracting overseas professionals [1][8][10] Group 1: Development of the Biomedicine Industry - The Guangzhou Development Zone and Huangpu District have built a complete biomedicine industry chain, integrating research, transformation, and production across different areas [1][4] - The core area of the Overseas Returnee Town has attracted around 30 well-known innovative enterprises, creating a positive cycle of talent and industry [3][4] - The "1+N" multi-core model of the town promotes regional collaboration and serves as a crucial hub for innovation [7][10] Group 2: Infrastructure and Support Systems - The dual centers, Phoenix Valley Overseas Returnee Center and International Biomedicine Innovation Center, provide comprehensive support services for the ecosystem [3][4] - The Guangzhou Guigu Technology Park serves as a demonstration area for the Overseas Returnee Town, focusing on innovation and entrepreneurship [4][6] - The establishment of a 20 billion yuan operational management guiding fund aims to attract social capital and enhance the development of the biomedicine sector [10][14] Group 3: Talent Attraction and Retention - The region has successfully attracted returning talents by offering favorable entrepreneurial policies and a conducive environment for innovation [8][10] - The integration of overseas talents into the local innovation network is facilitated by a ten-service operational system [6][12] - The returnee town is designed to support the rapid transformation of scientific achievements into marketable products [4][12] Group 4: Financial Support and Investment - A 50 billion yuan science and technology mother fund has been established to invest in strategic emerging industries, including those involving returning talents [13][14] - Approximately 76.11 billion yuan has been invested in 274 enterprises, with 18.54 billion yuan specifically allocated to returning entrepreneurial companies [14] - The innovative financial model allows for a 100% loss on single projects, effectively reducing early-stage investment risks [13][14]